Literature DB >> 10760748

Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta1.

L N Ramoshebi1, U Ripamonti.   

Abstract

Capillary invasion is a vital regulatory signal during bone morphogenesis that is influenced by angiogenic molecules such as fibroblast growth factor (FGF) and some members of the transforming growth factor-beta (TGF-beta) superfamily, including TGF-betas themselves. Bone morphogenetic proteins (BMPs), which are members of the TGF-beta superfamily, have previously not been shown to possess direct angiogenic properties. Osteogenic protein-1 (OP-1; BMP-7) is a potent regulator of cartilage and bone differentiation in vivo. The osteogenic and angiogenic properties of OP-1 at both ortho- and heterotopic sites in adult chacma baboons (Papio ursinus) are enhanced synergistically by the simultaneous application of relatively low doses of TGF-beta1. The single application of relatively high doses of TGF-beta1 (20 ng), and bFGF (500 ng) or relatively low (100 ng) and high (1,000 ng) doses of OP-1 in the chick chorioallantoic membrane (CAM) assay elicited a prominent and (for OP-1) dose-dependent angiogenic response. The binary application of a relatively low dose of OP-1 (100 ng) with a relatively low dose of bFGF (100 ng) or with a relatively low (5 ng) or high (20 ng) dose of TGF-beta1 resulted in a synergistic enhancement of the angiogenic response. The angiogenic effect of the relatively low doses of the combined morphogens was distinctly more pronounced than that of the single application of the relatively high doses of the respective factors. The present findings suggest that these morphogens may be deployed in binary combination in order to accentuate experimental angiogenesis. The cooperative interaction of the different morphogens in the CAM assay may provide important biological clues towards the control of clinical angiogenesis. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760748     DOI: 10.1002/(SICI)1097-0185(20000501)259:1<97::AID-AR11>3.0.CO;2-O

Source DB:  PubMed          Journal:  Anat Rec        ISSN: 0003-276X


  13 in total

1.  Immunomodulation of tissue-engineered transplants: in vivo bone generation from methylprednisolone-stimulated chondrocytes.

Authors:  Andreas Haisch; Frank Wanjura; Cornelia Radke; Korinna Leder-Jöhrens; Andreas Gröger; Michaela Endres; Svea Klaering; Alexander Loch; Michael Sittinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-07-25       Impact factor: 2.503

2.  Bone morphogenetic protein 7 increased vascular endothelial growth factor (VEGF)-a expression in human granulosa cells and VEGF receptor expression in endothelial cells.

Authors:  Ikumi Akiyama; Osamu Yoshino; Yutaka Osuga; Jia Shi; Miyuki Harada; Kaori Koga; Yasushi Hirota; Tetsuya Hirata; Tomoyuki Fujii; Shigeru Saito; Shiro Kozuma
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

Review 3.  Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates.

Authors:  David M Wiley; Suk-Won Jin
Journal:  Semin Cell Dev Biol       Date:  2011-10-12       Impact factor: 7.727

4.  Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.

Authors:  Yanli Song; Laura Coleman; Jianru Shi; Hideyuki Beppu; Kaori Sato; Kenneth Walsh; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-13       Impact factor: 4.733

5.  Isolation, characterization and investigation of differentiation potential of human periodontal ligament cells and dental follicle progenitor cells and their response to BMP-7 in vitro.

Authors:  Yahya Açil; Fan Yang; Aydin Gulses; Mustafa Ayna; Jörg Wiltfang; Matthias Gierloff
Journal:  Odontology       Date:  2015-03-11       Impact factor: 2.634

Review 6.  ALK1 as an emerging target for antiangiogenic therapy of cancer.

Authors:  Sara I Cunha; Kristian Pietras
Journal:  Blood       Date:  2011-04-05       Impact factor: 22.113

7.  Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.

Authors:  Seth E Karol; Leonard A Mattano; Wenjian Yang; Kelly W Maloney; Colton Smith; ChengCheng Liu; Laura B Ramsey; Christian A Fernandez; Tamara Y Chang; Geoffrey Neale; Cheng Cheng; Elaine Mardis; Robert Fulton; Paul Scheet; F Anthony San Lucas; Eric C Larsen; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Meenakshi Devidas; Mary V Relling
Journal:  Blood       Date:  2015-11-20       Impact factor: 22.113

8.  Recombinant human bone morphogenetic protein-7 enhances fracture healing in an ischemic environment.

Authors:  Chuanyong Lu; Zhiqing Xing; Yan-yiu Yu; Celine Colnot; Theodore Miclau; Ralph S Marcucio
Journal:  J Orthop Res       Date:  2010-05       Impact factor: 3.494

9.  Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.

Authors:  Sara I Cunha; Evangelia Pardali; Midory Thorikay; Charlotte Anderberg; Lukas Hawinkels; Marie-José Goumans; Jasbir Seehra; Carl-Henrik Heldin; Peter ten Dijke; Kristian Pietras
Journal:  J Exp Med       Date:  2010-01-11       Impact factor: 14.307

10.  GDF5 regulates TGFß-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides.

Authors:  Francesca Margheri; Nicola Schiavone; Laura Papucci; Lucia Magnelli; Simona Serratì; Anastasia Chillà; Anna Laurenzana; Francesca Bianchini; Lido Calorini; Eugenio Torre; Javier Dotor; Esperanza Feijoo; Gabriella Fibbi; Mario Del Rosso
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.